Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on MRNS. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Royal Bank of Canada dropped their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $0.54 on Wednesday. The stock has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.96. The stock has a market cap of $30.04 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $10.50.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of large investors have recently bought and sold shares of MRNS. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals in the second quarter valued at $727,000. Squarepoint Ops LLC acquired a new position in shares of Marinus Pharmaceuticals in the second quarter worth about $206,000. AQR Capital Management LLC boosted its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Marinus Pharmaceuticals during the 2nd quarter worth $64,000. Finally, Point72 DIFC Ltd acquired a new position in Marinus Pharmaceuticals in the second quarter worth about $28,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.